Journal of The American Academy of Dermatology, Dec 1, 1998
Pityriasis versicolor (ie, tinea versicolor) is a common superficial fungal infection caused by t... more Pityriasis versicolor (ie, tinea versicolor) is a common superficial fungal infection caused by the lipophilic yeast Malassezia furfur (also known as Pityrosporum ovale, P orbiculare), which is part of the normal flora of the human skin. 1-3 It is a chronically recurring infection characterized by the presence of hypopigmented or hyperpigmented white, salmon pink, red, or brown macules occurring primarily on the trunk and proximal extremities. 4 Tinea versicolor is one of the most common dermatologic disorders seen 944
Journal of the American Academy of Dermatology, 1998
Pityriasis versicolor (ie, tinea versicolor) is a common superficial fungal infection caused by t... more Pityriasis versicolor (ie, tinea versicolor) is a common superficial fungal infection caused by the lipophilic yeast Malassezia furfur (also known as Pityrosporum ovale, P orbiculare), which is part of the normal flora of the human skin. 1-3 It is a chronically recurring infection characterized by the presence of hypopigmented or hyperpigmented white, salmon pink, red, or brown macules occurring primarily on the trunk and proximal extremities. 4 Tinea versicolor is one of the most common dermatologic disorders seen 944
Antimicrobial Agents and Chemotherapy, Jul 1, 1998
The bioavailabilities and bioequivalences of single 200-mg doses of itraconazole solution and two... more The bioavailabilities and bioequivalences of single 200-mg doses of itraconazole solution and two capsule formulations were evaluated in a crossover study of 30 male volunteers. The two capsule formulations were bioequivalent. The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule. However, the maximum concentrations of the drug in plasma (C max), the times to C max , and the terminal half-lives were comparable for all three formulations. These data indicate that the bioavailabilities of itraconazole and hydroxyitraconazole are enhanced when administered as an oral solution instead of capsules.
This open-label, multicenter trial evaluated the efficacy and safety of a new oral solution formu... more This open-label, multicenter trial evaluated the efficacy and safety of a new oral solution formulation of itraconazole in HIV+/AIDS patients with fluconazole-refractory oropharyngeal candidiasis. Seventy-four HIV+/AIDS patients with mycologically confirmed oropharyngeal candidiasis who failed fluconazole therapy (200 mg/day) were treated with 100 mg of itraconazole oral solution administered twice daily (200 mg/day) for 14 days. Patients who demonstrated an incomplete response to treatment were treated for an additional 14 days (28 days total). Clinical responders were eligible for participation in a separate 6-month maintenance protocol. If they declined further treatment, responders were monitored for 6 weeks posttreatment. The primary efficacy parameter was clinical response (i.e., no lesions or symptoms) at end of treatment. Fungal cultures were performed at baseline and at the end of treatment. Among the 74 patients who had mycologically confirmed, fluconazole-unresponsive, oropharyngeal candidiasis at baseline, 41 (55%) achieved a clinical response by day 28. The median time to response was 7 days (range, 7 to 28 days). Candida albicans was the most common pathogen isolated, either alone (62%) or in combination with another Candida species (31%). All 22 patients who entered the optional, off-therapy, 6-week follow-up phase relapsed; mean time to relapse was 13 days. Itraconazole oral solution was well-tolerated; adverse events were predominantly gastrointestinal disturbances. This trial demonstrates that itraconazole oral solution is a useful therapy in the treatment of HIV-infected patients with fluconazole-refractory oropharyngeal candidiasis.
Journal of Veterinary Pharmacology and Therapeutics, 1983
The profile of the blood concentration of ampicillin us time was compared in 2 4 calves after amp... more The profile of the blood concentration of ampicillin us time was compared in 2 4 calves after ampicillin administration (10 mg/kg body weight) by the intratracheal (i.t.) and the intravenous (i.v.) routes in a crossover study. In a subsequent study, 12 of the calves were given ampicillin i.v. and 12 were given ampicillin i.t.; at 15 min and 2 h after drug administration, the calves were killed and lungs, kidneys, liver, urine and plasma were collected for ampicillin assay. The mean ampicillin concentration in blood after i.v. treatment was significantly (K O. 0 1) higher than after i.t. treatment. The mean ampicillin level in lungs after i.t. treatment was significantly higher than the level after i.v. treatment, but concentrations in kidneys, liver, urine and plasma after i.v. treatment were higher (but not significantly) than those after i.t. treatment.
Journal of The American Academy of Dermatology, Dec 1, 1998
Pityriasis versicolor (ie, tinea versicolor) is a common superficial fungal infection caused by t... more Pityriasis versicolor (ie, tinea versicolor) is a common superficial fungal infection caused by the lipophilic yeast Malassezia furfur (also known as Pityrosporum ovale, P orbiculare), which is part of the normal flora of the human skin. 1-3 It is a chronically recurring infection characterized by the presence of hypopigmented or hyperpigmented white, salmon pink, red, or brown macules occurring primarily on the trunk and proximal extremities. 4 Tinea versicolor is one of the most common dermatologic disorders seen 944
Journal of the American Academy of Dermatology, 1998
Pityriasis versicolor (ie, tinea versicolor) is a common superficial fungal infection caused by t... more Pityriasis versicolor (ie, tinea versicolor) is a common superficial fungal infection caused by the lipophilic yeast Malassezia furfur (also known as Pityrosporum ovale, P orbiculare), which is part of the normal flora of the human skin. 1-3 It is a chronically recurring infection characterized by the presence of hypopigmented or hyperpigmented white, salmon pink, red, or brown macules occurring primarily on the trunk and proximal extremities. 4 Tinea versicolor is one of the most common dermatologic disorders seen 944
Antimicrobial Agents and Chemotherapy, Jul 1, 1998
The bioavailabilities and bioequivalences of single 200-mg doses of itraconazole solution and two... more The bioavailabilities and bioequivalences of single 200-mg doses of itraconazole solution and two capsule formulations were evaluated in a crossover study of 30 male volunteers. The two capsule formulations were bioequivalent. The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule. However, the maximum concentrations of the drug in plasma (C max), the times to C max , and the terminal half-lives were comparable for all three formulations. These data indicate that the bioavailabilities of itraconazole and hydroxyitraconazole are enhanced when administered as an oral solution instead of capsules.
This open-label, multicenter trial evaluated the efficacy and safety of a new oral solution formu... more This open-label, multicenter trial evaluated the efficacy and safety of a new oral solution formulation of itraconazole in HIV+/AIDS patients with fluconazole-refractory oropharyngeal candidiasis. Seventy-four HIV+/AIDS patients with mycologically confirmed oropharyngeal candidiasis who failed fluconazole therapy (200 mg/day) were treated with 100 mg of itraconazole oral solution administered twice daily (200 mg/day) for 14 days. Patients who demonstrated an incomplete response to treatment were treated for an additional 14 days (28 days total). Clinical responders were eligible for participation in a separate 6-month maintenance protocol. If they declined further treatment, responders were monitored for 6 weeks posttreatment. The primary efficacy parameter was clinical response (i.e., no lesions or symptoms) at end of treatment. Fungal cultures were performed at baseline and at the end of treatment. Among the 74 patients who had mycologically confirmed, fluconazole-unresponsive, oropharyngeal candidiasis at baseline, 41 (55%) achieved a clinical response by day 28. The median time to response was 7 days (range, 7 to 28 days). Candida albicans was the most common pathogen isolated, either alone (62%) or in combination with another Candida species (31%). All 22 patients who entered the optional, off-therapy, 6-week follow-up phase relapsed; mean time to relapse was 13 days. Itraconazole oral solution was well-tolerated; adverse events were predominantly gastrointestinal disturbances. This trial demonstrates that itraconazole oral solution is a useful therapy in the treatment of HIV-infected patients with fluconazole-refractory oropharyngeal candidiasis.
Journal of Veterinary Pharmacology and Therapeutics, 1983
The profile of the blood concentration of ampicillin us time was compared in 2 4 calves after amp... more The profile of the blood concentration of ampicillin us time was compared in 2 4 calves after ampicillin administration (10 mg/kg body weight) by the intratracheal (i.t.) and the intravenous (i.v.) routes in a crossover study. In a subsequent study, 12 of the calves were given ampicillin i.v. and 12 were given ampicillin i.t.; at 15 min and 2 h after drug administration, the calves were killed and lungs, kidneys, liver, urine and plasma were collected for ampicillin assay. The mean ampicillin concentration in blood after i.v. treatment was significantly (K O. 0 1) higher than after i.t. treatment. The mean ampicillin level in lungs after i.t. treatment was significantly higher than the level after i.v. treatment, but concentrations in kidneys, liver, urine and plasma after i.v. treatment were higher (but not significantly) than those after i.t. treatment.
Uploads
Papers by Joseph Guarnieri